Stockscreener 앱 받기
1.79
3.76%
-0.07
시간 외 거래:
1.78
-0.01
-0.56%
전일 마감가:
$1.86
열려 있는:
$1.84
하루 거래량:
5.42M
Relative Volume:
0.60
시가총액:
$526.82M
수익:
$188.87M
순이익/손실:
$-400.38M
주가수익비율:
-1.4094
EPS:
-1.27
순현금흐름:
$-260.90M
1주 성능:
-7.25%
1개월 성능:
-6.28%
6개월 성능:
+30.66%
1년 성능:
-81.75%
1일 변동 폭
$1.75
$1.85
1주일 범위
$1.75
$1.96
52주 변동 폭
$1.16
$9.99
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.79 | 526.82M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
112.80 | 195.65B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
362.26 | 138.10B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
89.68 | 132.17B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
79.61 | 102.08B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.24 | 43.79B | 6.60B | 4.16B | 490.10M | 6.93 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
Why Is Pacific Biosciences of California, Inc. (PACB) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Target Price from Analysts - MarketBeat
State Street Corp Boosts Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Third Generation Sequencing Market Key Players Analysis - openPR
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownTime to Sell? - MarketBeat
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
China Neurogenomics Market Research 2024-2031, Profiles of Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, MGI Tech, Agilent, Revvity, Qiagen, Pacific Biosciences, Danaher, Oxford NanoporeResearchAndMarkets.com - WICZ
Fmr LLC Has $694,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences updates executive severance agreements By Investing.com - Investing.com Canada
Pacific Biosciences updates executive severance agreements - Investing.com India
Pacific Biosciences Updates Executive Severance Agreements - TipRanks
Pacific Biosciences of California, Inc. announced that it expects to receive $50 million in funding - Marketscreener.com
Long Read Sequencing Market Industry Dynamics - openPR
Why Pacific Biosciences of California (PACB) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
BNP Paribas Financial Markets Reduces Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Pacific Biosciences names CEO as interim CFO By Investing.com - Investing.com Australia
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpHere's Why - MarketBeat
Pacific Biosciences names CEO as interim CFO - Investing.com
Soros Fund Management LLC Grows Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACB (Pacific Biosciences of California) Net Issuance of Pr - GuruFocus.com
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight - Benzinga
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Hold" from Analysts - MarketBeat
PacBio Reports Equity Incentive Awards to New Employees Under Na - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Trading 7.4% HigherShould You Buy? - MarketBeat
Shrimp Hydrolysate Market Set to Surge to $675.9 Million with an Impressive 8.7% CAGR by 2034 - GlobeNewswire Inc.
SOFTBANK GROUP CORP. Acquires Significant Stake in Pacific Biosciences of California Inc - GuruFocus.com
PACB (Pacific Biosciences of California) 3-Year Revenue Gro - GuruFocus.com
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - Quantisnow
Senvest Management LLC Boosts Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y - MSN
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Sumitomo Mitsui Trust Group Inc. Has $20.17 Million Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Research Analysts Offer Predictions for PACB FY2024 Earnings - MarketBeat
DNA Sequencing Market to Grow by USD 17.34 Billion (2024-2028), Driven by Rising NGS Adoption, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by UBS Group to "Hold" Rating - MarketBeat
Pacific Biosciences CCO departs amid restructuring By Investing.com - Investing.com Australia
Pacific Biosciences CCO departs amid restructuring - Investing.com India
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Inc (PACB) Quarterly 10-Q Report - Quartzy
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
자본화:
|
볼륨(24시간):